The refortification of the tower of London 1679-1686PARNELL, G.Antiquaries (The) Journal London. 1983, Vol 63, Num 2, pp 337-352Article

The Refortification of the Tower of London 1679-86PARNELL, G.Antiquaries (The) Journal London. 1983, Vol 63, Num 2, pp 337-352Article

The Roman and medieval defences and the later development, of the Inmost Ward, Tower of London : excavations 1955-77PARNELL, G.Transactions of the London and Middlesex Archaeological Society. 1985, Vol 36, pp 1-79Article

Excavations at the Salt Tower, Tower of London, 1976PARNELL, G.Transactions of the London and Middlesex Archaeological Society. 1983, Vol 34, pp 95-106Article

An air mission planning algorithm using decision analysis and mixed integer programmingGRIGGS, B. J; PARNELL, G. S; LEHMKUHL, L. J et al.Operations research. 1997, Vol 45, Num 5, pp 662-676, issn 0030-364XArticle

Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the C_H2 domainsWAWRZYNCZAK, E; CUMBER, A. J; PARNELL, G. D et al.Molecular immunology. 1992, Vol 29, Num 2, pp 213-220, issn 0161-5890Article

Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A₁ chain and recombinant ricin A chainWAWRZYNCZAK, E. J; CUMBER, A. J; HENRY, R. V et al.International journal of cancer. 1991, Vol 47, Num 1, pp 130-135, issn 0020-7136, 6 p.Article

Purification of immunotoxins containing the ribosome-inactivating proteins gelonin and momordin using high performance liquid immunoaffinity chromatography compared with blue sepharose CL-6B affinity chromatographyCUMBER, A. J; HENRY, R. V; PARNELL, G. D et al.Journal of immunological methods. 1990, Vol 135, Num 1-2, pp 15-24, issn 0022-1759Article

Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugateCUMBER, A. J; SALLY WARD, E; WINTER, G et al.The Journal of immunology (1950). 1992, Vol 149, Num 1, pp 120-126, issn 0022-1767Article

The low uptake of an abrin A-chain immunotoxin by rat hepatic cells in vivo and in vitroSKILLETER, D. N; PRICE, R. J; PARNELL, G. D et al.Cancer letters. 1989, Vol 46, Num 3, pp 161-166, issn 0304-3835Article

Structural features of the antibody-A chain linkage that influence the activity and stability of ricin A chain immunotoxinsCUMBER, A. J; WESTWOOD, J. H; HENRY, R. V et al.Bioconjugate chemistry. 1992, Vol 3, Num 5, pp 397-401, issn 1043-1802Article

Structural factors influencing the pharmacokinetics and stability of immunotoxinsWAWRZYNCZAK, E. J; CUMBER, A. J; HENRY, R. V et al.Biochemical Society transactions. 1992, Vol 20, Num 4, pp 738-743, issn 0300-5127Conference Paper

Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome-inactivating protein α-sarcin from Aspergillus giganteusWAWRZYNCZAK, E. J; HENRY, R. V; CUMBER, A. J et al.European journal of biochemistry (Print). 1991, Vol 196, Num 1, pp 203-209, issn 0014-2956, 7 p.Article

Foundations 2025 : A value model for evaluating future air and space forcesPARNELL, G. S; CONLEY, H. W; JACKSON, J. A et al.Management science. 1998, Vol 44, Num 10, pp 1336-1350, issn 0025-1909Article

Effect of linkage variation on pharmacokinetics of ricin. A chain-antibody conjugates in normal ratsWORRELL, N. R; CUMBER, A. J; PARNELL, G. D et al.Anti-cancer drug design. 1986, Vol 1, Num 3, pp 179-188, issn 0266-9536Article

An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B chainECCLES, S. A; MACINTOSH, D. P; PURVIES, H. P et al.Cancer immunology and immunotherapy. 1987, Vol 24, Num 1, pp 37-41, issn 0340-7004Article

Ricin B chain converts a non-cytotoxic antibody-ricin A chain conjugate into a potent and specific cytotoxic agentMCINTOSH, D. P; EDWARDS, D. C; CUMBER, A. J et al.FEBS letters. 1983, Vol 164, Num 1, pp 17-20, issn 0014-5793Article

Pharmacokinetics in the rat of panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordinWAWRZYNCZAK, E. J; CUMBER, A. J; HENRY, R. V et al.Cancer research (Baltimore). 1990, Vol 50, Num 23, pp 7519-7526, issn 0008-5472, 8 p.Article